John Didsbury, PhD: Going Against the Grain in Established Alzheimer
The founder and CEO of T3D Therapeutics, Inc., spoke about T3D’s desire to go against the grain and trend in the therapeutic development for mild to moderate Alzheimer disease.
John Didsbury, PhD: Phase IIa Trial of T3D-959 in Mild to Moderate Alzheimer Disease
Study results suggest that agonist stimulation of PPAR delta may be an effective therapeutic strategy to addressing dysfunctional metabolism in Alzheimer disease.
2 Clarke Drive Cranbury, NJ 08512